GSK Material Request Form



Please fill out your details on the form provided and email to GSK Vaccines Department: elizabeth.x.lonie@gsk.com or post to GlaxoSmithKline, PO Box 18095 Melbourne 8003 **PLEASE PRINT IN BLOCK LETTERS**

Title:	Name:		Occupation:	
Organisation:				
Address:				
Phone:		Email:		
I would lil	ke to speak with a GSK Re	epresentative		

HEALTHCARE PROFESSIONAL RESOURCES













CONSUMER DISEASE AWARENESS RESOURCES





How you can stay informed with GSK.

GSK believes it is important to provide timely and useful information related to our medicines and vaccines to ensure you and your patients are well informed about GSK's product information. If you would like to embark on a digital journey with us, we will need your email consent.

Examples of what you can expect to receive:

- Scientific updates
- · Educational webinars and events (e.g. webinar invitations and post symposium highlights)
- · Information about our products
- Disease awareness materials (e.g. patient story videos, brochures)

To access the above please use the QR code or link: www.stayinformed.gskpro.com.au

PBS Information: This product is not listed on the PBS or the National Immunisation Program (NIP).

Please review Product Information before prescribing. Product Information can be accessed at www.gsk.com.au/arexvy



SCAN QR CODE to stay informed



▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reportingproblems

Indication: AREXVY is indicated for active immunisation of individuals 60 years and older for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV). Dosing and administration: AREXVY is administered as a single, reconstituted dose of 0.5 mL by intramuscular injection. The need for revaccination has not been established.

Safety: Very common adverse events (≥10%) are headache, myalgia, arthralgia, injection site pain and fatigue. Common adverse events (≥1%) are injection site erythema, injection site swelling, fever, chills and rhinorrhoea (not a complete list; see full PI).¹

Reference: 1. AREXVY Product Information.

We, GlaxoSmithKline Australia Pty Ltd ABN 47 100 162 481 collect, use and disclose personal information about you so we can perform our business activities and functions. We collect your personal information in order to send you direct marketing material and to contact you regarding our activities and products. We may disclose your personal information to third parties we use in the ordinary operations of our business, including our affiliates and third parties located overseas. If we do not collect your personal information, we may be unable to provide you with all of our services. Our privacy policy can be found at https://privacy.gsk.com/en-au/privacy-notice/general/ and contains information about how you may access and correct personal information held by us and how you can complain about a breach of privacy and how we will deal with such a complaint. If you require, you may access the information we hold about you by writing to the Privacy Officer, GlaxoSmithKline Australia Pty Ltd. PO Box 18095, Melbourne, Victoria, 8003.

To opt-out of receiving further communications from GSK, please unsubscribe.

For information on GSK products or to report an adverse event involving a GSK product, please contact GSK Medical Information on 1800 033 109. Trade marks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. GlaxoSmithKline Australia Pty Ltd, Melbourne, VIC. PM-AU-RSA-BROC-240001 Date of approval: October 2024.

HCP, Healthcare Professional; RSV, respiratory syncytial virus.